Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Withanone is a naturally occurring withanolide, a C28-steroidal lactone primarily derived from the medicinal plant *Withania somnifera* (Ashwagandha). It is recognized as a potent inhibitor of the mitochondrial chaperone protein GRP75 (also known as mortalin or HSPA9). By binding to GRP75, withanone disrupts its interaction with various proteins, such as p53, thereby inducing apoptosis in cancer cells or modulating cellular stress responses. Recent research has also identified its role in preventing CD28 internalization in T cells by inhibiting GRP75-mediated macropinocytosis, suggesting potential therapeutic applications in heart failure and immune dysregulation. While widely available as a component of dietary supplements, it is extensively utilized in preclinical research for its anti-cancer, neuroprotective, and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on withanone.